Lantern Pharma (NASDAQ:LTRN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lantern Pharma (NASDAQ:LTRN) from a sell rating to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Lantern Pharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $25.00.

Lantern Pharma Trading Up 1.6%

Shares of Lantern Pharma stock opened at $4.41 on Friday. The business’s fifty day simple moving average is $4.33 and its 200 day simple moving average is $3.79. The firm has a market capitalization of $47.63 million, a P/E ratio of -2.48 and a beta of 1.57. Lantern Pharma has a 12 month low of $2.55 and a 12 month high of $6.12.

Lantern Pharma (NASDAQ:LTRN) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.13. Analysts predict that Lantern Pharma will post -1.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantern Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LTRN. Perigon Wealth Management LLC grew its position in Lantern Pharma by 169.8% during the first quarter. Perigon Wealth Management LLC now owns 39,387 shares of the company’s stock worth $139,000 after buying an additional 24,787 shares in the last quarter. Westside Investment Management Inc. grew its position in Lantern Pharma by 17.1% during the second quarter. Westside Investment Management Inc. now owns 35,900 shares of the company’s stock worth $113,000 after buying an additional 5,250 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Lantern Pharma during the second quarter worth about $40,000. 28.62% of the stock is currently owned by hedge funds and other institutional investors.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.